Topical rapamycin (sirolimus) for treatment of cutaneous microcystic lymphatic malformation of the gluteal area - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue European Journal of Dermatology Année : 2019

Topical rapamycin (sirolimus) for treatment of cutaneous microcystic lymphatic malformation of the gluteal area

Résumé

Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions that result from abnormal embryological development of lymphatic vessels [1]. They present as clusters of vesicles that are full of lymph and blood. CMLMs commonly affect the lower limbs, gluteal areas, or the head and neck. The most frequent complications are oozing, bleeding, aesthetic impairment, pain, or bacterial infections. The management is challenging. Treatment options include surgery, laser therapy
Fichier non déposé

Dates et versions

hal-02619966 , version 1 (25-05-2020)

Identifiants

Citer

Sophie Leducq, Sandy Vrignaud, Gérard Lorette, Denis Herbreteau, Vincent Dubée, et al.. Topical rapamycin (sirolimus) for treatment of cutaneous microcystic lymphatic malformation of the gluteal area. European Journal of Dermatology, 2019, 29 (1), pp.82-83. ⟨10.1684/ejd.2018.3440⟩. ⟨hal-02619966⟩
33 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More